Cover Image

PAPERBACK
$49.00



View/Hide Left Panel

4
Options Considered

The committee considered several options relative to the use of the MTD as the highest dose for use in carcinogenicity screening studies. These options were initially proposed by the participants in the MTD workshop organized by the committee in consultation with the federal liaison group. The first option would retain the status quo, with the possible addition of lower doses in addition to the MTD. The second option would use a high dose that is an arbitrary fraction of the EMTD. The third option would redefine the MTD, basing it on studies of the dose dependence of physiologic effects expected to alter carcinogenic response. The fourth option would use MTD testing as part of an overall testing strategy that separates carcinogens from noncarcinogens and provides information useful for determining human relevance; this could take one of two forms—a two-track system that comprises full testing and limited testing and a system of sequential studies. These options are presented below and are followed by discussions of their advantages and disadvantages.

OPTION 1

Continue carcinogenicity screening studies with the MTD as the highest dose according to current practice (with the inclusion of lower doses as well).



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 53
OPTIONS CONSIDERED 53 original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution. 4 Options Considered The committee considered several options relative to the use of the MTD as the highest dose for use in carcinogenicity screening studies. These options were initially proposed by the participants in the MTD workshop organized by the committee in consultation with the federal liaison group. The first option would retain the status quo, with the possible addition of lower doses in addition to the MTD. The second option would use a high dose that is an arbitrary fraction of the EMTD. The third option would redefine the MTD, basing it on studies of the dose dependence of physiologic effects expected to alter carcinogenic response. The fourth option would use MTD testing as part of an overall testing strategy that separates carcinogens from noncarcinogens and provides information useful for determining human relevance; this could take one of two forms—a two-track system that comprises full testing and limited testing and a system of sequential studies. These options are presented below and are followed by discussions of their advantages and disadvantages. OPTION 1 Continue carcinogenicity screening studies with the MTD as the highest dose according to current practice (with the inclusion of lower doses as well).